Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Mansard

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Annales De Dermatologie Et De Venereologie|July 28, 2007
[Regression in primary cutaneous melanoma is not predictive for sentinel lymph node micrometastasis]A Alquier-Bouffard, F Franck, J Joubert-Zakeyh, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 30, 2021
Clinical, biological and histological characteristics of bullous pemphigoid associated with anti-PD-1/PD-L1 therapy: A national retrospective studyC Juzot, V Sibaud, F Amatore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 27, 2016
Merkel cell carcinoma: value of sentinel lymph-node status and adjuvant radiation therapyA Servy, E Maubec, P E Sugier, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 18, 2023
Duration of treatment with cemiplimab in advanced cutaneous squamous cell carcinoma in complete response: Real-life studyK Khelef, E Maubec, G Jeudy, et al.
ESMO Open|November 3, 2023
Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAF<sup>V600</sup>-mutated melanomaJ Y Blay, C Cropet, S Mansard, et al.
Annales De Dermatologie Et De Venereologie|February 7, 2024
The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concernsM Amini-Adle, J-P Arnault, F Aubin, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Annales De Dermatologie Et De Venereologie|July 28, 2007
[Regression in primary cutaneous melanoma is not predictive for sentinel lymph node micrometastasis]A Alquier-Bouffard, F Franck, J Joubert-Zakeyh, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 30, 2021
Clinical, biological and histological characteristics of bullous pemphigoid associated with anti-PD-1/PD-L1 therapy: A national retrospective studyC Juzot, V Sibaud, F Amatore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 27, 2016
Merkel cell carcinoma: value of sentinel lymph-node status and adjuvant radiation therapyA Servy, E Maubec, P E Sugier, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 18, 2023
Duration of treatment with cemiplimab in advanced cutaneous squamous cell carcinoma in complete response: Real-life studyK Khelef, E Maubec, G Jeudy, et al.
ESMO Open|November 3, 2023
Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAF<sup>V600</sup>-mutated melanomaJ Y Blay, C Cropet, S Mansard, et al.
Annales De Dermatologie Et De Venereologie|February 7, 2024
The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concernsM Amini-Adle, J-P Arnault, F Aubin, et al.
Pageof 2